Foamable formulation
US9107823B2 · kind B2 · utility
1Cited by
16References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 6, 2012 |
| Grant date | Aug 18, 2015 |
| Priority date | — |
| Expiry date | May 21, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.